Pubblicazioni internazionali

  • Viswanath B et al. Cellular models to study bipolar disorder: A systematic review. J Affect Disord. 2015; 184:36-50 [abs]
  • Costa M et al. Preliminary transcriptome analysis in lymphoblasts from cluster headache and bipolar disorder patients implicates dysregulation of circadian and serotonergic genes. J Mol Neurosci. 2015; 56:688-95 [abs]
  • Cadeddu G et al.  Clozapine toxicity due to a multiple drug interaction: a case report.  J Med Case Rep. 2015 9:77 [abs]
  • Bauer M et al. Influence of light exposure during early life on the age of onset of bipolar disorder. J Psychiatr Res. 2015; 64:1-8 [abs]
  • Milanesi E et al. Insulin-like growth factor 1 differentially affects lithium sensitivity of lymphoblastoid cell lines from lithium responder and non-responder bipolar disorder patients. J Mol Neurosci. 2015 Mar 5. [Epub ahead of print] [abs]
  • Bocchetta A et al. Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Medicine 2015; 13:12 [abs]
  • Hunsberger JG et al.  Novel integrative genomic tool for interrogating lithium response in bipolar disorder. Translational Psychiatry 2015; 5: e504 [abs]
  • International Genomics of Alzheimer’s Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimer’s and Dementia 2014 Dec 20. pii: S1552-5260(14)02492-3. [Epub ahead of print] [abs]
  • Bauer M et al. Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. European Psychiatry 2015; 30: 99-105 [abs]
  • Niola P et al. Lithium-induced differential expression of SAT1 in suicide completers and controls is not correlated with polymorphisms in the promoter region of the gene. Psychiatry Research 2014; 220: 1167-1168.
  • Bauer M et al. Relationship between sunlight and the age of onset of bipolar disorder: an international multisite study. J Affect Disord 167: 104-11, 2014. [abs]
  • Escott-Price V et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease. PLoS One 9: e94661, 2014. [abs]
  • Floris G et al.  C9ORF72 repeat expansion and bipolar disorder – is there a link? No mutation detected in a Sardinian cohort of patients with bipolar disorder. Bipolar Disorders 16: 667-8, 2014.
  • Del Zompo M et al. Association study in three different populations between the GPR88 gene and major psychoses. Mol Genet Genomic Med 2: 152-9, 2014. [abs]
  • Deiana V et al. Continuation versus discontinuation of lithium during pregnancy: a retrospective case series. J Clin Psychopharmacol 34: 407-10, 2014.
  • Lambert JC et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics 45: 1452-8, 2013. [abs]
  • Pisanu C et al. No association of endocannabinoid genes with bipolar disorder or lithium response in a Sardinian sample”. Psychiatry Res 210: 887-90, 2013. [abs]
  • Manchia M et al.  Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One 8: e65636, 2013. [abs]
  • Squassina A et al. Differential effect of lithium on spermidine/spermine N1-acetyltransferase expression in suicidal behaviour. Int J Neuropsychopharmacol 16: 2209-18, 2013. [abs]
  • Manchia M et al. Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disorders 15: 496-506, 2013. [abs]
  • Squassina A et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol Res 73: 1-7, 2013. [abs]
  • Severino G et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics 14: 655-674, 2013. [abs]
  • Bocchetta A et al. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Medicine 11: 33, 2013. [abs]
  • Costa M et al. Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-α gene (PPARA) and schizophrenia. European Neuropsychopharmacology 23: 749-59, 2013. [abs]
  • Lambert JC et al. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer’s disease. Mol Psychiatry 18: 461-470, 2013. [abs]
  • Stochino ME et al. Evaluation of lithium response in episodic cluster headache: a retrospective case series. Headache 52: 1171-1175, 2012. [abs]
  • Bauer M et al.  Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disorders 14: 654-663, 2012. [abs]
  • Squassina A et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 12: 1559-1569, 2011. [abs]
  • Deiana V et al. A retrospective case series of bipolar patients with adjunctive carbamazepine in long-term lithium treatment: evaluation of the effectiveness. J Clin Psychopharmacol 31: 538-540, 2011.
  • Genin E et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry 16: 903-907, 2011. [abs]
  • Squassina A. et al. Age at onset in bipolar disorder: Investigation of the role of TaqIA polymorphism of DRD2 gene in a Sardinian sample. European Psychiatry 26: 141-143, 2011. [abs]
  • Lambert JC et al. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging 32: 756.e11-5, 2011. [abs]
  • Tozzi F et al. Admixture analysis of age at onset in bipolar disorder. Psychiatry Research 185: 27-32, 2011. [abs]
  • Squassina A, Manchia M, Del Zompo M. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Human Genomics and Proteomics, 159761, 2010. [abs]
  • Lambert JC et al. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer’s disease: a meta-analysis study. Journal of Alzheimers Disease 22: 247-255, 2010. [abs]
  • Squassina A et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11: 1149-1167, 2010. [abs]
  • Del Zompo M et al. Genome-scan for bipolar disorder with sib-pair families in the Sardinian population: a new susceptibility locus on chromosome 1p22-p21?. Am J Med Genet B Neuropsychiatr Genet 153B: 1200-1208, 2010. [abs]
  • Schulze TG et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 62: 72-78, 2010. [abs]
  • Asuni C et al. Mixture analysis of age at onset in migraine without aura: evidence for three subgroups. Headache 50: 1313-1319, 2010. [abs]
  • Squassina A et al. NRG1 and BDNF genes in schizophrenia: an association study in an Italian case-control sample. Psychiatry Research 176: 82-84, 2010. [abs]
  • Manchia M et al. Interacting genes in lithium prophylaxis: preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neuroscience Letters 467: 67-71, 2009. [abs]
  • Manchia M et al. No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Research 169: 164-166, 2009. [abs]
  • Asuni C et al. Migraine and tumour necrosis factor gene polymorphism. An association study in a Sardinian sample. Journal of Neurology 256: 194-197, 2009. [abs]
  • Squassina A et al. The diacylglycerol kinase eta (DGKH) gene and bipolar disorder: a replication study in a Sardinian sample. Molecular Psychiatry 14: 350-351, 2009.
  • Severino G et al. Association study in a Sardinian sample between Bipolar Disorder and the nuclear receptor REV-ERBα gene, a critical component of the circadian clock system. Bipolar Disorders 11: 215-220, 2009. [abs]
  • Squassina A. et al. A case-control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatric Genetics 18: 128-132, 2008 [abs]
  • Squassina A et al. The PDLIM5 gene and lithium prophylaxis: An association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacological Research 57: 369-73, 2008 [abs]
  • Manchia M et al. Age at onset in Sardinian bipolar I patients: evidence for three subgroups. Bipolar Disorders 10: 443-446, 2008 [abs]
  • Bocchetta A et al. Long term lithium treatment and survival from external causes including suicide. J Clin Psychopharmacol  27: 544-546, 2007 [abs]
  • Piccardi MP et al. Alzheimer’s disease: case-control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 144: 895-899, 2007 [abs]
  • Asuni C et al. Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain 8: 185-9, 2007 [abs]
  • Bocchetta A et al. Fifteen-year follow-up of thyroid function in lithium patients”. J Endocrinol Invest 30: 363-366, 2007 [abs]
  • Del Zompo M et al. Haplotype association study between DRD1 gene and bipolar type I affective disorder in two samples from Canada and Sardinia”. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 144B: 237-241, 2007 [abs]
  • Ghiani ME et al. Genetic, demographic and archival study on a Sardinian village. In: Human Genetic Isolates, eds. C. Calò and G. Vona, Research Signpost, Kerala (India); pp. 131-149, 2006.
  • Galderisi S et al. COMT VAL158Met and BDNF C270T polymorphisms in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 52: 83-89, 2005 [abs]
  • Severino G et al. A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. American Journal of Medical Genetics (Neuropsychiatric Genetics) 134B: 37-38, 2005 [abs]
  • Galderisi S et al. COMT VAL158Met and BDNF C270T polymorphisms in schizophrenia: a case-control study. Schizophrenia Research 73: 27-30, 2005 [abs]
  • Severino G et al. Adverse drug reactions during imatinib and lansoprazole treatment in GIST. The Annals of Pharmacotherapy 39: 162-164, 2005 [abs]
  • Severino G, Del Zompo M. Adverse drug reactions: role of pharmacogenomics. Pharmacological Research 49: 363-373, 2004 [abs]
  • Cousin E et al. Association studies in candidate genes: strategies to select SNPs to be tested. Human Heredity 56: 151-159, 2003.
  • Stochino ME et al. Association study between the phenotype migraine without aura – panic disorder and dopaminergic receptor genes. Pharmacological Research 48: 531-534, 2003 [abs]
  • Severino G et al. Pharmacogenomics: state of the research and perspectives in clinical application. Neurological Sciences 24 (Suppl. 2): S146-8, 2003 [abs]
  • Piccardi MP et al. Manic-depressive illness: association study with the inositol polyphosphate 1-phosphatase and serotonin transporter genes. Psychiatric Genetics 12:23-27, 2002 [abs]
  • Cherchi A, Del Zompo M. “Pharmacology”. In: Headache and Migraine in Childhood and Adolescence, eds. V. Guidetti, G. Russell, M. Sillanpaa, P. Winner, Martin Dunitz, London, pp. 37-47, 2002.
  • Zuddas A, Del Zompo M. “Neurochemistry”. In: Headache and Migraine in Childhood and Adolescence, eds. V. Guidetti, G. Russell, M. Sillanpaa, P. Winner, Martin Dunitz, London, pp. 19-36, 2002.
  • Bocchetta A et al. Association of personal and familial suicide risk with low serum cholesterol concentration in male lithium patients. Acta Psychiatrica Scandinavica 104: 37-41, 2001 [abs]
  • Cherchi A et al. Role of dopaminergic system in migraine. Journal of Headache and Pain 2:S47-S49, 2001.
  • Paoletti AM et al. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. The Journal of Clinical Endocrinology & Metabolism 86, 608-612, 2001.
  • Del Zompo M. Dopaminergic hypersensitivity in migraine: Clinical and genetic evidence. Functional Neurology 15 (Suppl. 3): 163-170, 2000 [abs]
  • Cherchi A et al. Positive association between dopamine D2 receptor gene and migraine without aura in a Sardinian sample. In: Frontiers in Headache Research vol. 8, “The Genetic of Headache Disorders”, eds. J. Olesen and M-G. Bousser, Lippincott Williams & Wilkins, Philadelphia, pp. 211-215, 2000.
  • Bocchetta A et al. Family-based association study between bipolar disorder and DRD2, DRD4 and SERT in Sardinia. American Journal of Medical Genetics (Neuropsychiatric Genetics), 88, 522-526, 1999 [abs]
  • Bocchetta A et al. Maternal inheritance of manic depression in hemizygotes for the G6PD-Mediterranean mutation. Indirect evidence for Xq28 transmission in Sardinia”. Psychiatric Genetics 9, 63-68, 1999 [abs]
  • Morelli M et al. Induction of fos-like immunoreactivity in the central extended amygdala by antidepressant drugs”. Synapse 31, 1-4, 1999 [abs]
  • Del Zompo M et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51, 781-786, 1998 [abs]
  • Bocchetta A et al. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. Journal of Clinical Psychopharmacology 18, 384-389, 1998 [abs]
  • Lai M et al. Therapy of migraine by modulating dopamine hypersensitivity: its effect on mood and pain. International Journal of Clinical Pharmacological Research 17, 101-103, 1997 [abs]
  • Piccardi MP et al. No evidence of association between dopamine D3 receptor gene and bipolar affective disorder. American Journal of Medical Genetics (Neuropsychiatric Genetics) 74, 137-139, 1997 [abs]
  • Bocchetta A et al. Carbamazepine augmentation in lithium refractory bipolar patients: a prospective study on long-term prophylactic effectiveness. Journal of Clinical Psychopharmacology 17, 92-96, 1997 [abs]
  • Ruiu S et al. Heterogeneity of monoaminergic vesicular carriers: pharmacological evidence using MPP+ as a marker. Life Sciences 59, 1703-1710, 1996 [abs]
  • Loi V et al. Sumatriptan and panic-like symptoms.  American Journal of Psychiatry 153: 1505, 1996 [abs]
  • Bocchetta A et al. Six-year follow-up of thyroid function during lithium treatment. Acta Psychiatrica Scandinavica 94, 45-48, 1996 [abs]
  • Del Zompo M et al. Dopamine hypersensitivity in migraine: role in apomorphine syncope. Headache 35, 222-224, 1995 [abs]
  • Del Zompo M et al. Thyroid function during carbamazepine. Biological Psychiatry 36, 135-136, 1994 [abs]
  • Bocchetta A, Piccardi MP, Del Zompo M. Is bipolar disorder linked to Xq28? Nature Genetics 6, 224, 1994 [abs]
  • Bocchetta A et al. A double-blind study of l-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatrica Scandinavica 88, 434-439, 1993 [abs]
  • Martinelli V et al. An interaction between carbamazepine and fluvoxamine. British Journal of Clinical Pharmacology 36, 615-616, 1993 [abs]
  • Bocchetta A et al. Genetic linkage and association studies in affective disorders. In: Psychiatry and Advanced Technologies, Eds. L. Ravizza, F. Bogetto, E. Zanalda, Raven Press Ltd., New York, pp. 283-287, 1993.
  • Del Zompo M et al. Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. British Journal of Pharmacology 109, 411-414, 1993 [abs]
  • Vaccari A et al. Differential interaction of 1-methyl-4-phenylpyridinium ion with the putatively vesicular binding site of [3H]tyramine in dopaminergic and nondopaminergic brain regions. Journal of Neurochemistry 60, 758-760, 1993 [abs]
  • Bocchetta A et al. The course of thyroid abnormalities during lithium treatment: a two-year follow-up study. Acta Psychiatrica Scandinavica 86, 38-41, 1992 [abs]
  • Del Zompo M et al. Localization of MPP+ binding sites in the brain of various mammalian species. Journal of Neural Transmission [P-D Sect] 4, 181-190, 1992 [abs]
  • Del Zompo M. Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes. Brain Research 571, 354-357, 1992 [abs]
  • Del Zompo M et al. Association and linkage studies of affective disorders. In: “Biological Psychiatry” vol. 2, Eds. G. Racagni, N. Brunello, T. Fukuda, Elsevier Sci. Publ., pp. 446-448, 1991.
  • Del Zompo M et al. A double-blind study of minaprine versus amitriptyline in major depression. Neuropsychobiology 24, 79-83, 1991.
  • Gessa GL et al.  SCH 23390 and psychosis. The Lancet 338, 185-186, 1991.
  • Del Zompo M et al. High-affinity binding of [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location. European Journal of Pharmacology 202, 293-294, 1991.
  • Burrai C, Bocchetta A, Del Zompo M. Mania and fluvoxamine.  American Journal of  Psychiatry 48, 263-1264, 1991.
  • Gessa GL et al. Lack of acute antispychotic effect of SCH 23390, a selective dopamine D1 receptor antagonists. The Lancet 337, 854-855, 1991.
  • Bocchetta A et al. Thyroid abnormalities during lithium treatment.  Acta Psychiatrica Scandinavica 83, 193-198, 1991 [abs]
  • Bocchetta A et al. Familial rates of affective illness in Sardinia with special reference to schizoaffective disorder. European Archives of Psychiatry and Clinical Neuroscience 240, 16-20, 1990 [abs]
  • Bocchetta A, Del Zompo M. Bipolar affective disorder and heterozygous beta-thalassaemia.  American Journal  of Psychiatry 147, 1094, 1990.
  • Bernardi F, Del Zompo M. Clozapine in idiopathic Parkinson’s disease. Neurology  40, 1151-1152, 1990.
  • Del Zompo M. 3H-MPP+ binding sites in mouse brain: pharmacological and biological characterization. Journal of Neurochemistry 54, 1905-1910, 1990 [abs].
  • Del Zompo M. Pharmacological characterization of 3H-MPP+ binding sites. In: “Aging Brain and Dementia: New Trends in Diagnosis and Therapy”, Eds.  L. Battistin, F. Gerstenbrand, Alan R. Liss, New York, pp. 273-280, 1990.
  • Del Zompo M et al. Clinical evidence for a role of dopaminergic system in depressive syndromes.  In: “Dopamine and Mental Depression”, Advances in the Biosciences vol. 77,  Eds.  G.L. Gessa, G. Serra, Pergamon Press, pp. 177-184, 1990.
  • Del Zompo M et al. Genetic markers in affective disorders in Sardinia. In: “The Modes of Depression: Psychobiology and Psychodynamics”, eds. L. Ravizza, E. Genazzani, R. Torta, C. Eva, Edizioni Libraria Cortina, Torino, pp. 143-149, 1989.
  • Ruiu S et al. Correspondence between 3H-MPP+ binding site and MAO-A enzyme: pharmacological evidences. Pharmacological Research 21 (Suppl. 1): 15-16, 1989.
  • Marongiu ME et al. Evaluation of the toxicity of the dopaminergic neurotoxins MPTP and MPP+ in PC12 pheochromocytoma cells: binding and biological studies. Neuroscience Letters 94, 349-354, 1988 [abs]
  • Corsini GU et al. Covalent protein binding of a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mouse and monkey brain in vitro and in vivo.  Biochemical Pharmacology 37, 4163-4169, 1988 [abs]
  • Corongiu FP et al. MPTP fails to induce lipid peroxidation in vivo. Biochemical Pharmacology 35, 2251-2253, 1987 [abs]
  • Corsini GU et al. Characterization of  [3H]MPTP binding sites. In: “Parkinson’s disease”, Advances in Neurology vol. 45, Eds. M.S. Yahr and K.J. Bergmann, , Raven Press, New York, pp. 153-158, 1987.
  • Del Zompo M et al. Properties of  3H-MPTP binding sites in human blood platelets. Life Sciences 39, 1885-1892, 1986 [abs]
  • Del Zompo M et al. High affinity binding sites for l-methyl-4-phenyl-pyridinium ion (MPP+) are present in mouse brain. European Journal of Pharmacology 129, 87-92, 1986 [abs]
  • Corsini GU et al. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.  Journal of Pharmacology and Experimental Therapeutics 238, 648-652, 1986 [abs]
  • Corsini GU et al. In vitro MAO type B dependent formation of an alkylating metabolite from 3H-MPTP in rat and monkey brain. In: “MPTP: a neurotoxin producing a parkinsonian syndrome”, eds.  S.P. Markey, M. Castagnoli Jr, A.J. Trevor, I.J. Kopin, Academic Press, New York, pp. 371-376, 1986.
  • Corsini GU et al. Primate-rodent 3H-MPTP binding differences and biotrasformation of MPTP to a reactive intermediate in vitro. Journal of Neural Transmission  22 (Suppl.), 55-60, 1986 [abs]
  • Del Zompo M et al. Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studies. Brain Research 378, 320-324, 1986 [abs]
  • Del Zompo M et al. Dopamine agonists in the treatment of schizophrenia.  In: “Progress in Brain Research” vol. 65, Eds.  J.M. Van Ree and S. Matthysse, Elsevier Publishers B.V., pp. 41-48, 1986.
  • Bocchetta A et al. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro. Journal of Neurochemistry 45, 673-676, 1985 [abs]
  • Corsini GU et al. Therapeutic efficacy of a partial dopamine agonist in drug-free Parkinsonian patients.  Journal of Neural Transmission 64, 105-111, 1985 [abs]
  • Del Zompo M et al. Deprenyl selectively inhibits [3H]MPTP binding sites in monkey brain. European Journal of Pharmacology 107, 285-286, 1985.
  • Del Zompo M et al. Inhibition of 3H-MPTP binding to rat brain by pargyline. Biochemical Pharmacology 33, 4105-4107, 1984.
  • Del Zompo M et al. Peripheral benzodiazepine binding sites in kidney: modifications by diabetes insipidus. Life Sciences 35, 2095-2013, 1984 [abs]
  • Del Zompo M et al. Dopaminergic system and clincal aspects of depression. Clinical Neuropharmacology 7 (Suppl.1), 926-927, 1984.
  • Del Zompo M et al. Linkage between X-chromosome markers and manic-depressive illness. Two Sardinian pedigrees. Acta Psychiatrica Scandinavica 70, 282-287, 1984 [abs]
  • Del Zompo M et al. Prophylactic efficacy of carbamazepine in lithium-resistant affective disorders. In: “Current Trends in Lithium and Rubidium Therapy”, Ed. G.U. Corsini, MTP Press Limited, Lancaster, UK, pp. 325-330, 1984.
  • Del Zompo M et al. Lithium treatment in schizoaffective patients. In: “Current Trends in Lithium and Rubidium Therapy”, Ed. G.U.Corsini, MTP Press, Limited, Lancaster, UK, pp. 142-150; 1984.
  • Del Zompo M et al. Properties of benzodiazepine binding sites in peripheral tissues. In: “Benzodiazepine Recognition Site Ligands: Biochemistry and Pharmacology”, Eds. G. Biggio and E. Costa, Raven Press, New York, pp. 239-248; 1983.
  • Del Zompo M, Post R, Tallman JF. Properties of two benzodiazepine binding sites in spinal cord. Neuropharmacology 22, 115-118, 1983 [abs]
  • Del Zompo M et al. Increased paroxysmal activity of partial seizures in man by apomorphine. Psychopharmacology 79, 209-214, 1983 [abs]
  • Corsini GU et al. The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology 20: 1309-1313-1981.
  • Del Zompo M et al. Antipsychotic effect of apomorphine: a retrospective study. In: “Apomorphine and Other Dopaminomimetics vol. 2, Clinical Pharmacology”, Eds. G.U. Corsini and G.L. Gessa, Raven Press, New York, pp. 65-76; 1981.
  • Corsini et al. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. The Lancet i (8122), 954-956, 1979 [abs]
  • Corsini GU et al. (-) Sulpiride as a specific antagonist of “low-dose” effects of apomorphine in man. In: “Sulpiride and Other Benzamides”, Eds.  P.F. Spano, M. Trabucchi, G.U. Corsini, G.L. Gessa, IBRF Press, Milano, pp. 255-267, 1979.
  • Corsini GU et al. Parkinsonism by haloperidol and piribedil. Psychopharmacology 59, 139-141, 1978 [abs]
  • Corsini GU et al. Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sciences 20, 1613-1618, 1977.
  • Corsini GU et al. Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. In: “Advances in Biochemical Psychopharmacology”, Eds. E. Costa and G.L. Gessa, Raven Press, New York, vol 16, pp 645-648, 1977.
  • Corsini GU et al. Therapeutical efficacy of a combination of apomorphine with Sulpiride or Metoclopramide  in Parkinsonism. Psychopharmacology 47, 169-173; 1976.

 

Progetto Unica